From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Papillomavirus Research
Available online 22 March 2018
Are two doses of human papillomavirus vaccine sufficient for girls aged 15–18 years? Results from a cohort study in India
Neerja Bhatla, Bhagwan M. Nene, Smita Joshi, Pulikottil O. Esmy, Usha Rani Reddy Poli, Geeta
Joshi, Yogesh Verma, Eric Zomawia, Sharmila Pimple, Priya R. Prabhu, Partha Basu, Richard
Muwonge, Sanjay Hingmire, Catherine Sauvaget, Eric Lucas, Michael Pawlita, Tarik Gheit, Kasturi Jayant, Sylla G Malvi, Maqsood Siddiqi, Angelika Michel, Julia Butt, Subha Sankaran, Thiraviam Pillai Rameshwari Ammal Kannan, Rintu Varghese, Uma Divate, Martina Willhauck-
Fleckenstein, Tim Waterboer, Martin Müller, Peter Sehr, Alka Kriplani, Gauravi Mishra, Radhika
Jadhav, Ranjit Thorat, Massimo Tommasino, M. Radhakrishna Pillai, Rengaswamy Sankaranarayanan
Abstract

Extending two-dose recommendations of HPV vaccine to girls between 15–18 years will reduce program cost and improve compliance. Immunogenicity and vaccine targeted HPV infection outcomes were compared between 1795 girls aged 15–18 years receiving two (1–180 days) and 1515 girls of same age receiving three (1–60-180 days) doses. Immunogenicity outcomes in 15–18 year old two-dose recipients were also compared with the 10–14 year old three-dose (N=2833) and two-dose (N=3184) recipients. The 15–18 year old two-dose recipients had non-inferior L1-binding antibody titres at seven months against vaccine-targeted HPV types compared to three-dose recipients at 15–18 years and three-dose recipients at 10–14 years of age. Neutralizing antibody titres at 18 months in 15–18 year old two-dose recipients were non-inferior to same age three-dose recipients for all except HPV 18. The titres were inferior to those in the 10–14 year old three-dose recipients for all targeted types. Frequency of incident infections from vaccine-targeted HPV types in the 15–18 year old two-dose recipients was similar to the three dose recipients. None of the girls receiving two or three doses had persistent infection from vaccine-targeted types. These findings support that two doses of HPV vaccine can be extended to girls aged 15–18 years.